“Chronic non-cancer pain conditions included neuropathic pain, fibromyalgia, rheumatoid arthritis, and mixed chronic pain.”
“Overall the quality of trials was excellent. Fifteen of the eighteen trials that met the inclusion criteria demonstrated a significant analgesic effect of cannabinoid as compared with placebo and several reported significant improvements in sleep.”
“There were no serious adverse effects. Adverse effects most commonly reported were generally well tolerated, mild to moderate in severity and led to withdrawal from the studies in only a few cases.”
“Overall there is evidence that cannabinoids are safe and modestly effective in neuropathic pain with preliminary evidence of efficacy in fibromyalgia and rheumatoid arthritis.”
“This observational study provides information on the patterns of cannabis use for therapeutic purposes among a group of patients with FM. Most of them were middle-aged women that did not respond to current treatment and self-administered marijuana, devoid of medical advice.”
28 people with fibromyalgia who were herbal cannabis users and 28 non-users, without differences in demographics and clinical variables, were compared. After two hours of cannabis use, there was a statistically significant reduction of pain and stiffness, enhancement of relaxation and an increase in somnolence and feeling of well-being (all P values < 0.001).
One case series of 172 participants reported from Germany included 32 people with fibromyalgia. On average, participants received delta 9-THC 7.5 mg over seven months.
“In our patient sample, THC treatment led to a significant reduction in pain intensity. Noteworthy, this effect could be observed when a mean daily dose of 7.5 mg THC was administered. This dosage shows high acceptance and efficacy.”